tbuckley/cabot-search huggingface dataset:
Primary endocrine therapy with anastrozole for early operable primary breast cancer in the elderly: Early clinical and biological data
Authors: K. L. Cheung, M. W. Ying, A. R. Green, A. Agrawal, C. E. Paish, L. Winterbottom, I. O. Ellis
Journal: Journal of Clinical Oncology (2006)

10647 Background: The initial treatment for early operable primary breast cancer (PBC) is surgery. Primary endocrine therapy with tamoxifen has been used in the elderly with estrogen receptor positive (ER+) PBC who refuse or are unfit for surgery. Current randomized data showed superiority of aromatase inhibitors (AIs) over tamoxifen in neoadjuvant, adjuvant and metastatic settings, it is possible that AIs may be a better therapeutic option in this context. We report the early clinical and biological data in using primary anastrozole for ER+ operable PBC in the elderly. Methods: Elderly (&gt; 70) patients with ER+ early operable PBC (&lt; 5cm), who refused or were unfit for surgery, and who had contraindications to tamoxifen, were treated with anastrozole 1mg daily as primary endocrine therapy. All had disease assessable by UICC criteria and received treatment for ≥ 6 months unless they progressed prior. Standard immunohistochemical staining was performed on tumor tissue, obtained by core biopsy, for ER, progesterone receptor (PgR) and HER2. Positivity for ER and PgR was defined by H-score ≥ 50, and HER2 positivity was defined as 3+. Results: Thirty-two patients received anastrozole as described during a two-year period. Thirty (93.8%) patients reached clinical benefit (CB = objective response (OR) + durable stable disease) at 6 months, with 11 (34.4%) ORs (complete response + partial response). Anastrozole was well tolerated with no patients withdrawn due to side effects. All patients had ER+ tumors. The response status at 6 months is stratified according to PgR and HER2 is shown in the table . Conclusions: Early clinical data has shown excellent efficacy and tolerability of anastrozole as primary endocrine therapy for early operable PBC in the elderly. The PgR and HER2 status did not appear to predict response within this group of ER+ tumors, but there was a trend towards a better quality of response (more ORs) for PgR positive/ HER2 negative tumors. Follow-up for longer-term efficacy assessment is continuing. [Table: see text] [Table: see text]
Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China, January to February 2020
Authors: Yuanyuan Xing, Pingzheng Mo, Yu Xiao, Oiu Zhao, Yongxi Zhang, Fan Wang
Journal: Eurosurveillance (2020)

Since December 2019, 62 medical staff of Zhongnan Hospital in Wuhan, China have been hospitalised with coronavirus disease 2019. During the post-discharge surveillance after clinical recovery, swabs were positive in two asymptomatic cases (3.23%). Case 1 had presented typical clinical and radiological manifestations on admission, while manifestation in Case 2 was very mild. In conclusion, a small proportion of recovered patients may test positive after discharge, and post-discharge surveillance and isolation need to be strengthened.
ANATOMIC PREDICTORS OF CORONARY OBSTRUCTION IN PATIENTS UNDERGOING TAVR FOR NATIVE AORTIC STENOSIS: AN ANAYLSIS OF THE INTERNATIONAL, MULTI-CENTER COBRA-TAVR REGISTRY
Authors: John Cyril Lisko, Norihiko Kamioka, Vasilis Babaliaros, Shinichi Shirai, Tomohiro Kawaguchi, Giuseppe Muscogiuri, Laura Fusini, Gianluca Pontone, Masanori Yamamoto, Ai Kagase, Norio Tada, Masaki Miyasaka, Masahiro Yamawaki, Yosuke Honda, Samuel Maidman, Sung-Han Yoon, Isida Byku, Raj R. Makkar, Gaetano Paone, Kendra Grubb, Jaffar Khan, Toby Rogers, Patrick Gleason, Robert Lederman, Adam Greenbaum
Journal: Journal of the American College of Cardiology (2020)
APPLICATION OF THE TIMI HEART FAILURE RISK SCORE TO THE EMPA-REG OUTCOME POPULATION
Authors: Subodh Verma, Abhinav Sharma, Bernard Zinman, Anne Pernille Ofstad, David Fitchett, Martina Brueckmann, Christoph Wanner, Isabella Zwiener, Jyothis T. George, Silvio E. Inzucchi, Javed Butler, C David Mazer
Journal: Journal of the American College of Cardiology (2020)
DECREASE IN HEMOGLOBIN AND ITS ASSOCIATION WITH ACUTE KIDNEY INJURY AFTER PERCUTANEOUS CORONARY INTERVENTION
Authors: Toshiki Kuno, Yohei Numasawa, Mitsuaki Sawano, Nozomi Niimi, Masaki Kodaira, Masahiro Suzuki, Koji Ueno, Ikuko Ueda, Keiichi Fukuda, Shun Kohsaka
Journal: Journal of the American College of Cardiology (2020)
HIGH DENSITY LIPOPROTEIN SUBFRACTIONS ARE ASSOCIATED WITH COGNITIVE PERFORMANCE: A CROSS-SECTIONAL ANALYSIS
Authors: Giuliano Generoso, Claudia K. Suemoto, Isabela Bensenor, Raul Santos, Steven R. Jones, Krishnaji Kulkarni, Michael Blaha, Peter Toth, Paulo Lotufo, Marcio Bittencourt
Journal: Journal of the American College of Cardiology (2020)
Ongoing Gender Inequity in Leadership Positions of Academic Oncology Programs
Authors: Laila A. Gharzai, Reshma Jagsi
Journal: JAMA Network Open (2020)

Mudit Chowdhary, MD; Akansha Chowdhary, MD; Trevor J. Royce, MD, MS, MPH; Kirtesh R. Patel, MD; Arpit M. Chhabra, MD; Shikha Jain, MD; Miriam A. Knoll, MD; Neha Vapiwala, MD; Barbara Pro, MD; Gaurav Marwaha, MD
Effect of matrix metallopeptidase 13 (MMP13) on multiple myeloma (MM) cells, osteoclast (OCL) activity, and bone resorption.
Authors: Jing Fu, Shirong Li, Rentian Feng, Mei Hua Jin, Farideh Sabeh, Stephen Weiss, Suzanne Lentzsch
Journal: Journal of Clinical Oncology (2012)

8099 Background: MM cells produce OCL-activating factors that induce excessive bone resorption resulting in lytic lesions. The role of MMPs in invasion/progression of solid tumors is well-known, but its function in MM has not been well elucidated. Our group has shown that MMP13 is highly expressed in primary MM cells and in sera of MM patients. Levels of MMP13 significantly correlate with the extent of bone disease. MMP13 is induced by IL-6 via AP-1 activation in MM cells and enhances fusion of OCL precursors resulting in excessive bone resorption. OCL formation using MNCs of mmp-13 -/- mice resulted in a fusion defect, significantly decreased OCL size and activity, which could be reversed by exogenous MMP13 (ASH 2009, IMW 2011). Methods: Methods will be presented in the Results section. Results: RT-PCR and western blotting revealed that IL-6 treatment of MM cells induced MMP13 transcription (30-fold) and secretion (&gt;1000-fold). Protein expression of the AP-1 members c-Jun and c-Fos was induced by IL-6, which correlated with MMP13 upregulation. Our data further indicate that the catalytic activity of MMP13 is not required to enhance OCL formation and bone resorption. To prove this, we generated the MMP13 activity-dead mutation MMP13-E223A construct by site-directed mutagenesis PCR-based cloning. The mutated protein was overexpressed in HEK293 cells and purified from the supernatant to confirm whether loss of catalytic activity blocks MMP13 function. To further investigate the in vivo role of MMP13 in MM bone disease, MMP13 expression was knocked down (KD) in murine 5TGM1-MM cells by pKLO. 1 puro lentiviral infection containing sh-RNA targeting mouse MMP13 sequence. MMP13-KD 5TGM1-MM cells or WT-5TGM1-MM cells were intratibially injected into RAG2 -/- mice. Development of lytic bone lesions are monitored by micro-QCT and data will be available at the time of presentation. Conclusions: Our data suggest that MMP13, secreted by MM cells, plays a critical role in the development of lytic lesions. Targeting MMP13 represents a promising approach to treat or to prevent bone disease in MM.
Gentamicin Induces Laminin 332 and Improves Wound Healing in Junctional Epidermolysis Bullosa Patients with Nonsense Mutations
Authors: Andrew Kwong, Jon Cogan, Yingping Hou, Richard Antaya, Michelle Hao, Gene Kim, Vadim Lincoln, Qiuyang Chen, David T. Woodley, Mei Chen
Journal: Molecular Therapy (2020)

Generalized severe junctional epidermolysis bullosa (GS-JEB) is an incurable and fatal autosomal recessively inherited blistering skin disease caused by mutations in the LAMA3, LAMB3, or LAMC2 genes. Most of these mutations are nonsense mutations that create premature termination codons that lead to impaired production of functional laminin 332, a protein needed for epidermal-dermal adherence. Gentamicin induces readthrough of nonsense mutations and restores the full-length protein in various genetic diseases. Using primary keratinocytes from three GS-JEB patients, we showed that gentamicin induced functional laminin 332 that reversed a JEB-associated, abnormal cell phenotype. In a subsequent open-label trial involving the same patients, we examined whether 0.5% gentamicin ointment applied topically to open skin wounds could promote nonsense mutation readthrough and create new laminin 332 in the patients' skin. Gentamicin-treated wounds exhibited increased expression of laminin 332 at the dermal-epidermal junction for at least 3 months and were associated with improved wound closure. There were no untoward side effects from topical gentamicin. The newly induced laminin 332 did not generate anti-laminin 332 autoantibodies in either the patients' blood or skin. Gentamicin readthrough therapy may be a treatment for GS-JEB patients with nonsense mutations.
TRENDS IN PREVALENCE OF E-CIGARETTE USE AMONG U.S. ADULTS. BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM, 2016 AND 2017
Authors: Mahmoud Al Rifai, Anwar Merchant, Vijay Nambi, Xiaoming Jia, Christie M. Ballantyne, Salim Virani
Journal: Journal of the American College of Cardiology (2020)
QIM20-127: A Team-Based Model to Promoting Hospice Utilization in High Risk Oncology Patients Through Individual Care Plan Development
Authors: Mohammad Khan, Benjamin Switzer, Sarah Lee, Joseph Hooley, Christa Poole, Girish Chandra Kunapareddy, Ruth Lagman, Alberto Montero
Journal: Journal of the National Comprehensive Cancer Network (2020)

"QIM20-127: A Team-Based Model to Promoting Hospice Utilization in High Risk Oncology Patients Through Individual Care Plan Development" published on 20 Mar 2020 by National Comprehensive Cancer Network.
TEMPORAL TRENDS OF NEXT-DAY DISCHARGE TAVR: ANALYSIS FROM NATIONWIDE READMISSIONS DATABASE (2012-2016)
Authors: Brian Case, Charan Yerasi, Byomesh Tripathi, Yanying Wang, Brian Forrestal, Anees Musallam, Rebecca Torguson, Itsik Ben-Dor, Hector M. Garcia-Garcia, William S. Weintraub, Toby Rogers, Ron Waksman
Journal: Journal of the American College of Cardiology (2020)
A phase II study of cabazitaxel in patients with previously treated metastatic gastroesophageal adenocarcinoma.
Authors: Trevor Clark Austin, Kimberly Perez, Lucia Fontes-Borts, Denise Luppe, Maureen Jean, Adam J. Olszewski, Kayla Rosati, Bharti Rathore, Howard Safran
Journal: Journal of Clinical Oncology (2013)

e15095 Background: Cabazitaxel is a semi-synthetic novel taxane with activity in docetaxel refractory prostate cancer. We sought to determine the response rate of cabazitaxel in patients with advanced gastroesophageal adenocarcinoma that had progressed after at least 1 prior therapy for metastatic disease. Methods: This open label single arm phase II study followed a Simon two-stage design. The study was designed to differentiate between a 10% level of activity and a 30% level of activity and was to be terminated if the response rate was unlikely to be &gt; 10%. Eligibility criteria included patients with gastroesophageal cancer with measurable disease after at least 1 prior regimen for metastatic disease. ECOG PS 0-2; ANC &gt; 1,500/µL, AST/ALT ≤ 3x ULN, total bili ≤ ULN. Pts initially received cabazitaxel 25 mg/m 2 IV every 21 days but after 9 patients were entered, the dose was reduced to 20 mg/m 2 due to toxicity. Results: The data safety monitoring board (DSMB) reviewed data after 13 pts were entered. Pt characteristics included 11 men, 2 women; median age, 70 yrs [range, 55-80]. Nine pts had ≥ 2 prior regimens. Ten pts had previous treatment with a taxane. Of 13 pts, no objective antitumor responses were observed and all 13 developed evidence of disease progression. A median of 2 cycles were given, up to a maximum of 6 cycles in 2 pts. The PFS rate at 3 months was 15%. The DSMB considered cabazitaxel ineffective and terminated the study. The probability of erroneously concluding the treatment was active (p ≥ 0.3) was &lt; 0.0419. Grade 3 or 4 adverse events occurred in 6 pts (46.1%), in which neutropenia (n=4) and pneumonia (n=1) were grade 4. Grade 3 toxicities included ANC (n=1), anemia (n=2), nausea (n=2), weakness (n=2), diarrhea (n=1), pleural effusion (n=1), typhilitis (n=1), vomiting (n=1). Conclusions: Cabazitaxel monotherapy demonstrated no antitumor efficacy in previously treated gastroesophageal cancer. Clinical trial information: NCT01365130.
Survival benefit from maintenance therapy after first-line chemotherapy in advanced non-small cell lung cancer: A meta-analysis.
Authors: Kader Chouahnia, Gaetan Des Guetz, Bernard Uzzan, Patrick Nicolas, Jean F. Morere
Journal: Journal of Clinical Oncology (2012)

e18003 Background: Maintenance therapy corresponds to a prolonged treatment after induction chemotherapy (CT) for patients with advanced non-small cell lung cancer (NSCLC). Several recent randomized controlled trials (RCTs) showed a survival benefit for maintenance therapy, especially for EGFR tyrosine-kinase inhibitors (TKIs), but conflicting results have been published. We performed a meta-analysis of all RCTs published either as articles or in abstract form. Since its presentation at ESMO 2011, this meta-analysis has been updated with one additional study (AVAPERL) and the preliminary data of PARAMOUNT on Overall Survival (OS). Methods: A PubMed query using several keywords simultaneously (NSCLC, maintenance, RCT, survival) found 79 references. Abstracts from ASCO and ESMO proceedings were also reviewed. References were cross-checked. Outcomes were OS and PFS (Progression Free Survival). We used a fixed-effect model when heterogeneity was absent and a random-effect model when present. We used EasyMA software. Results: Thirteen RCTs were included with IFCT-GFPC trial used twice since it assessed 2 maintenance therapies in parallel, gemcitabine and erlotinib. These 13 RCTs included 5251 patients (median age 61 years, 4261 stage IV, 913 stage III diseases, 2929 adenocarcinomas, 983 squamous cell carcinomas). For OS (14 sub-studies), the overall HR was 0.85 (95 % Confidence Interval or CI 0.80-0.91; fixed effect model). For PFS (13 sub-studies), the overall HR was 0.65 (CI 0.58-0.73; random effect model). Both continuation maintenance (6 RCTs, HR 0.87, CI 0.76-0.99) and switch maintenance (3 RCTs, HR 0.85, CI 0.75-0.98) significantly improved OS. Targeted therapies also significantly increased OS (5 RCTs, HR 0.85, CI 0.77-0.93). Anaemia, thrombocytopenia and neutropenia were significantly more frequent after maintenance chemotherapy, and skin rashes and diarrhoea after biotherapies. Conclusions: Maintenance therapy with either continuation or switch chemotherapy or EGFR TKIs significantly improved OS and PFS. The benefit-to-risks ratios of these 3 types of maintenance should be compared more precisely thanks to additional RCTs.
Lipid Accumulation in Hearts Transplanted From Nondiabetic Donors to Diabetic Recipients
Authors: Raffaele Marfella, Cristiano Amarelli, Francesco Cacciatore, Maria Luisa Balestrieri, Gelsomina Mansueto, Nunzia D’Onofrio, Salvatore Esposito, Irene Mattucci, Gemma Salerno, Marisa De Feo, Michele D’Amico, Paolo Golino, Ciro Maiello, Giuseppe Paolisso, Claudio Napoli
Journal: Journal of the American College of Cardiology (2020)

Early pathogenesis of diabetic cardiomyopathy (DMCM) may involve lipotoxicity of cardiomyocytes in the context of hyperglycemia. There are many preclinical studies of DMCM pathogenesis, but the human evidence is still poorly understood.By using a nondiabetic mellitus (non-DM) heart transplanted (HTX) in diabetes mellitus (DM) recipients, this study conducted a serial study of human heart transplant recipients evaluating cardiac effects of diabetic milieu (hyperglycemia and insulin resistance) on lipotoxic-mediated injury. We evaluated cardiomyocyte morpho-pathology by seriated biopsies of healthy implanted hearts in DM recipients during 12-month follow-up from HTX. Because metformin reduces ectopic lipid accumulation, we evaluated the effects of the drug in a nonrandomized subgroup.The DMCM-AHEAD (Diabetes and Lipid Accumulation and Heart Transplant) prospective ongoing study (NCT03546062) evaluated 158 first HTX recipients (82 non-DM, 76 DM of whom 35 [46%] were receiving metformin). HTX recipients were undergoing clinical standard evaluation (metabolic status, echocardiography, coronary computed tomography angiography, and endomyocardial biopsies). Biopsies evaluated immune response, Oil Red-O staining, ceramide, and triacylglycerol levels. Lipotoxic factors and insulin resistance were evaluated by reverse transcriptase-polymerase chain reaction.There was a significant early and progressive cardiomyocyte lipid accumulation in DM but not in non-DM recipients (p = 0.019). In the subgroup receiving metformin, independently from immunosuppressive therapy that was similar among groups, lipid accumulation was reduced in comparison with DM recipients not receiving the drug (hazard ratio: 6.597; 95% confidence interval: 2.516 to 17.296; p < 0.001). Accordingly, lipotoxic factors were increased in DM versus non-DM recipients, and, relevantly, metformin use was associated with fewer lipotoxic factors.Early pathogenesis of human DMCM started with cardiomyocyte lipid accumulation following HTX in DM recipients. Metformin use was associated with reduced lipid accumulation independently of immunosuppressive therapy. This may constitute a novel target for therapy of DMCM.
PREDICTORS OF CALCIFIC AORTIC VALVE STENOSIS PROGRESSION AS MEASURED BY CHANGE IN PEAK VELOCITY: A META-ANALYSIS AND META-REGRESSION
Authors: Navneet Sharma, Sareena George, Ramsey Kalil, Prateek Sharma, Paul Kim, Clive Goulbourne, Smadar Kort, Dmitriy Feldman, Puja Parikh
Journal: Journal of the American College of Cardiology (2020)
USEFULNESS OF EICOSAPENTAENOIC ACID TO ARACHIDONIC ACID RATIO AS DIFFERENTIATION OF STEMI AND NSTEMI/UAP
Authors: Ryo Okubo, Rine Nakanishi, Hiroto Aikawa, Shingo Matsumoto, Ryota Noike, Takayuki Yabe, Hideo Amano, Mikihito Toda, Takanori Ikeda
Journal: Journal of the American College of Cardiology (2020)
Meeting the Educational Needs of an Increasingly Diverse Surgical Workforce
Authors: Mara B. Antonoff, Elizabeth H. Stephens, Shanda H. Blackmon
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
大動脈弁逆流症のHill徴候と重症度 | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: Maruyama Naoki, Shiraishi Hirokazu, Shirayama Takeshi, Fujioka Ayumu, Mera Kayoko, Uchihashi Motoki, Yanishi Kenji, Naito Daisuke, Nakanishi Naohiko, Akakabe Yoshiki, Kato Taku, Taniguchi Takuya, Koide Masahiro, Nakamura Takeshi, Yamano Tetsuhiro, Matsumuro Yoshiaki, Sawada Takahisa, Matsubara Hiroaki
Journal: Circulation (2013)
Sensory nerves regulate mesenchymal stromal cell lineage commitment by tuning sympathetic tones
Authors: Bo Hu, Xiao Lv, Hao Chen, Peng Xue, Bo Gao, Xiao Wang, Gehua Zhen, Janet L. Crane, Dayu Pan, Shen Liu, Shuangfei Ni, Panfeng Wu, Weiping Su, Xiaonan Liu, Zemin Ling, Mi Yang, Ruoxian Deng, Yusheng Li, Lei Wang, Ying Zhang, Mei Wan, Zengwu Shao, Huajiang Chen, Wen Yuan, Xu Cao
Journal: Journal of Clinical Investigation (2020)

The sensory nerve was recently identified as being involved in regulation of bone mass accrual. We previously discovered that prostaglandin E2 (PGE2) secreted by osteoblasts could activate sensory nerve EP4 receptor to promote bone formation by inhibiting sympathetic activity. However, the fundamental units of bone formation are active osteoblasts, which originate from mesenchymal stromal/stem cells (MSCs). Here, we found that after sensory denervation, knockout of the EP4 receptor in sensory nerves, or knockout of COX-2 in osteoblasts, could significantly promote adipogenesis and inhibit osteogenesis in adult mice. Furthermore, injection of SW033291 (a small molecule that locally increases the PGE2 level) or propranolol (a beta blocker) significantly promoted osteogenesis and inhibited adipogenesis. This effect of SW033291, but not propranolol, was abolished in conditional EP4-KO mice under normal conditions or in the bone repair process. We conclude that the PGE2/EP4 sensory nerve axis could regulate MSC differentiation in bone marrow of adult mice.
INPATIENT CORONARY ANGIOGRAPHY IS ASSOCIATED WITH REDUCED MORTALITY IN PATIENTS AGED &gt;85 YEARS WITH NON-ST-ELEVATION MYOCARDIAL INFARCTION
Authors: Alexandra Murphy, Anoop Koshy, Phelia Kunniardy, Georgie Meehan, Jay Ramchand, H.M. Omar Farouque, David Clark, Matias Yudi
Journal: Journal of the American College of Cardiology (2020)
IRREGULAR PROTRUSION IS CORRELATED WITH DEVELOPMENT OF NEOATHEROSCLEROSIS AFTER 2NDAND 3RDGENERATION DRUG-ELUTING STENT IMPLANTATION: OPTICAL COHERENCE TOMOGRAPHIC STUDY
Authors: Kyosuke Yanagawa, Ryu Shutta, Hiroaki Nohara, Taku Toyoshima, Naoko Higashino, Hitoshi Nakamura, Yutaka Matsuhiro, Koji Yasumoto, Masaki Tsuda, Akihiro Tanaka, Naotaka Okamoto, Yasuharu Matsunaga-Lee, Masamichi Yano, Masaki Yamato, Yasuyuki Egami, Masami Nishino, Jun Tanouchi
Journal: Journal of the American College of Cardiology (2020)
TRENDS IN HOSPITALIZATION AND OUTCOMES OF HEART FAILURE WITH DIABETES IN THE US: DATA FROM THE NATIONAL INPATIENT SAMPLE (2004-2015)
Authors: Menatalla Mekhaimar, Soha Dargham, Mohamed Elshazly, Jassim Al Suwaidi, Hani Jneid, Charbel Abi Khalil
Journal: Journal of the American College of Cardiology (2020)
LEFT VENTRICULAR SYSTOLIC EJECTION TIME IS AN INDEPENDENT PREDICTOR OF ALL-CAUSE MORTALITY IN HEART FAILURE WITH REDUCED EJECTION FRACTION
Authors: Alia Saed Alhakak, Morten Sengeløv, Peter Jørgensen, Niels Eske Bruun, Ulrik Abildgaard, Allan Iversen, Thomas Fritz Hansen, John Teerlink, Fady Malik, Scott D. Solomon, Gunnar Gislason, Tor Biering-Sorensen
Journal: Journal of the American College of Cardiology (2020)